StockNews.AI
ARGX
StockNews.AI
27 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

1. Pomerantz LLP investigates potential securities fraud against argenx. 2. FDA alerts on Vyvgart Hytrulo's risks, possibly requiring regulatory action. 3. On June 30, 2025, ARGX shares fell 1.59% due to FDA concerns. 4. The investigation may affect investor confidence in argenx's leadership. 5. Legal issues could lead to significant financial liabilities for the company.

3m saved
Insight
Article

FAQ

Why Bearish?

Concerns over product risks can lead to reduced investor confidence, reflected in recent price drop.

How important is it?

The investigation and FDA concerns directly impact stakeholders' perceptions and stock valuation.

Why Short Term?

Immediate effects due to investigation and FDA alert but long-term impact depends on resolution.

Related Companies

VRTXABBVMNK
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether argenx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 30, 2025, the U.S. Food and Drug Administration (“FDA”) issued an alert on a potential signal of serious risks associated with argenx’s Vyvgart Hytrulo product, stating that the treatment has a potential risk of “severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy” based on reports to the FDA Adverse Event Reporting System. The alert also said that the “FDA is evaluating the need for regulatory action.” On this news, argenx’s American Depositary Share (“ADS”) price fell $8.92 per ADS, or 1.59%, to close at $551.22 per ADS on June 30, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News